So excited to hear @ycommodore.bsky.social discuss “Hypertension: Local & Global Interventions” at the PCNA Annual Symposium

The Cost of Cutting NIH Research: Voices from the Frontlines tradeoffs.org/2025/03/13/c.... Thank you @tradeoffs.org for the opportunity to reflect with Laura López.

The Cost of Cutting NIH Research: Voices from the Frontlines

A candid conversation between a professor and a Ph.D. candidate about potential NIH funding cuts and their impact on the future of medical research.

tradeoffs.org

Sweet… first set of pods dropped!! I loved hosting the @ahascience.bsky.social podcast series: The Link between #CKD and #CVD #CKMSyndrome Check out the link below for the pods and toolkit professional.heart.org/en/education... Though AHA may want to think twice about using my voice 🤷‍♂️😅

The Link between CKD and CVD

Discover the importance of early CKD testing and diagnosis to improve patient outcomes. Access our podcast series, toolkit, & educational resources for healthcare professionals.

professional.heart.org

I’m grateful for all the wonderful memories created at #AHA24. Until we meet again at #AHA25 in #NOLA! @rantocran.bsky.social @bunmiogungbe.bsky.social @modeldoc.bsky.social

We now have @ycommodore.bsky.social discussing her work in LINKED-BP, an @ahascience.bsky.social health-Equity research network project #AHA24 #AHAMeeting

Starting off strong with presentations from Drs Susmita Parashar, Yvonne Commodore-Mensah and Khadijah Breathett #AHA24 @ahascience.bsky.social

Starting us off is Dr. Keith B. Churchwell, the president of the AHA #AHA24 @ahascience.bsky.social

We’re building on 100 years of hope this year at #AH24. The Centennial Experience captures 100 years of #cardiology history, make time for it this weekend at Scientific Sessions. Thank you for joining us and inspiring us into our second century. 🎥: @dramitkhera.bsky.social

BPROAD presented at #AHA24 showed in those w/ type 2 diabetes & elevated systolic blood pressure (SBP), intensive SBP lowering (<120 mmHg) reduced major adverse CV events (MACE) by 21% compared to standard treatment (<140 mmHg). Watch this for one attendee’s take on the data.

Tirzepatide is another option for managing obesity and CVD and improving quality of life in patients with HFpEF & obesity. Watch this video for perspective on the data presented at #AHA24. #cardiology